However, future additional experimental validation of CSF2 and its regulation, as well as proper exclusion of IL-13 and TSLP in the effects of NCTD on CRC or other types of tumor cells may provide further insights into the particular anticancer mechanism of NCTD. The gene discussed is CSF2; the disease is colorectal carcinoma.